PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.93%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-15.04%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-960.92%
Negative EBIT growth while Healthcare median is 8.93%. Seth Klarman would check if external or internal factors caused the decline.
-1383.16%
Negative operating income growth while Healthcare median is 2.16%. Seth Klarman would check if structural or cyclical issues are at play.
-825.75%
Negative net income growth while Healthcare median is 2.44%. Seth Klarman would investigate factors dragging net income down.
-782.35%
Negative EPS growth while Healthcare median is 2.02%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-500.00%
Negative diluted EPS growth while Healthcare median is 2.50%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
5.01%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.01%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
85.85%
OCF growth exceeding 1.5x Healthcare median of 9.20%. Joel Greenblatt would see if a superior business model or cost structure drives strong cash generation.
50.46%
FCF growth exceeding 1.5x Healthcare median of 10.88%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
21610.35%
10Y CAGR of 21610.35% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-58.90%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-34.59%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
83.84%
OCF/share CAGR near Healthcare median of 83.06%. Charlie Munger might attribute it to typical industry growth patterns.
96.51%
5Y OCF/share growth exceeding 1.5x Healthcare median of 59.94%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
93.36%
3Y OCF/share growth > 1.5x Healthcare median of 54.63%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-1432.24%
Negative 10Y net income/share CAGR vs. Healthcare median of 34.87%. Seth Klarman might see a fundamental problem if peers maintain growth.
-4510.94%
Negative 5Y CAGR while Healthcare median is 33.23%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-1077.29%
Negative 3Y CAGR while Healthcare median is 26.90%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
1098.12%
Equity/share CAGR exceeding 1.5x Healthcare median of 27.00% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-52.70%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-68.46%
Negative 3Y equity/share growth while Healthcare median is -13.33%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.31%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-0.98%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-18.81%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-25.50%
Negative BV/share change while Healthcare median is -0.31%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-7.99%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
41.67%
R&D growth of 41.67% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-14.49%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.